SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A sharp selloff amid broader biotech weakness and options-expiration trading has focused discussion on SELLASs pending REGAL Phase 3 milestone and topline data. Bears cite the prolonged quiet period and delayed 80th-event update as reasons for concern, while bulls argue the decline is market- and options-driven and are waiting for trial results.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs proposed index-screening rules, which could put Strategys index membership at risk, are the main focus, with traders concerned about potential forced selling and added pressure on the shares. Others argue the impact is limited or already priced in and are buying the dip, while Bitcoins weakness adds to the bearish debate.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

PANWs sharp decline is being linked by some traders to CISAs listing of an exploited PAN-OS management-interface flaw, while broader weakness in software and cybersecurity stocks and valuation concerns also feature in the discussion. Traders disagree on whether the selloff is an overdone dip to buy or a warning of further downside; the flaw is described as narrow, with fixes available and limited exploitation.

TOSHI

TOSHI is drawing attention around hopes for a technical breakout after trading in a prolonged range, with traders pointing to chart patterns, buying activity, and a possible short squeeze. Many holders are accumulating and remain bullish, while others warn that repeated resistance, weak price action, and broader crypto-market weakness could lead to further declines; listing and project-update talk remains speculative.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereums recent pullback amid broader crypto weakness has traders focused on whether support will hold. The discussion is split between bearish calls for further downside and bullish claims that the dip is a bear trap and an opportunity to accumulate.

Aventus Network

AVT is drawing attention amid a volatile rebound and elevated trading activity in a thinly traded, low-float token, with traders speculating that sustained buying could trigger a breakout or squeeze. Aventus Clouds decentralized-compute updates add a bullish project narrative, while concerns about concentrated holdings, selling pressure and the exploit-related selloff temper that optimism.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Traders are linking reports of possible plague cases across several countries to Arcturuss self-amplifying mRNA vaccine platform, speculating about future infectious-disease vaccine demand; no ARCT program or deal tied to the outbreak is established. Separately, investors are debating the companys OTC deficiency Phase 2 update and LUNAR 2.0 platform, balancing encouraging signals against concerns about development timelines.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET is drawing attention amid a steep selloff that traders often attribute to weakness across semiconductors and AI-infrastructure stocks, alongside doubts about AI spending and higher-rate pressures. The debate centers on whether its photonics technology and customer relationships can translate into scaled shipments and revenue: bulls see a long-term AI-optics opportunity, while skeptics point to limited commercial proof and concerns about managements execution and communication.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novos steep selloff and concerns that it is losing ground to Eli Lilly in obesity drugs dominate the discussion, with traders also criticizing management and questioning the pipeline and growth outlook after the companys strategy update. Bulls counter that oral Wegovy demand and pipeline investments could support a recovery, while many remain skeptical ahead of Q3 results.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude prices climb on fears that Iran-related conflict, tanker attacks, and Saudi/Houthi tensions could disrupt oil production and shipping through key routes. Traders are divided between expecting a prolonged supply shock and warning that a ceasefire or easing tensions could unwind the war premium, leaving the fund highly sensitive to headlines.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


88aadirect

88Aa direct